Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study-Reference-Cited by-同舟云学术

Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study

Published:2017-11-15 Issue:3 Volume:32 Page:403-410
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Bissonnette R.¹,Haydey R.²,Rosoph L.A.³,Lynde C.W.⁴,Bukhalo M.⁵,Fowler J.F.⁶,Delorme I.⁷,Gagné-Henley A.⁸,Gooderham M.⁹,Poulin Y.¹⁰,Barber K.¹¹,Jenkin P.¹²,Landells I.¹³,Pariser D.M.¹⁴

Affiliation:

1. Innovaderm Research; Montreal QC Canada

2. Winnipeg Clinic; Winnipeg MB Canada

3. North Bay Dermatology Centre; North Bay ON Canada

4. Lynderm Research; Markham ON Canada

5. Altman Dermatology Associates; Arlington Heights IL USA

6. Dermatology Specialists Research; Louisville KY USA

7. Dr Isabelle Delorme Inc.; Drummondville QC Canada

8. Dre Angélique Gagné-Henley MD Inc.; Saint-Jérôme QC Canada

9. Dr. Melinda Gooderham SKiN Centre for Dermatology; Peterborough ON Canada

10. Centre de Recherche Dermatologique du Québec Métropolitain; Québec QC Canada

11. Kirk Barber Research; Calgary AB Canada

12. Dermatology Associates; Seattle WA USA

13. Nexus Clinical Research; St. John's NL Canada

14. Department of Dermatology; Eastern Virginia Medical School and Virginia Clinical Research Inc.; Norfolk VA USA

Funder

AbbVie

Amgen

Apopharma

Boehringer Ingelheim

Celgene

Dermira

Eli Lilly and Company

Galderma

GlaxoSmithKline

Incyte

Janssen

Kineta

LEO Pharma Research Foundation

Merck

Novartis

Pfizer

Regeneron Pharmaceuticals

Tribute

Xenoport

Valeant Pharmaceuticals International

Innovaderm Research

Moberg Pharma

Vitae

Abbott Fund

Bickel Biotechnology

Biofrontera AG

DUSA Pharmaceuticals

Novo Nordisk

Ortho Dermatologics

Peplin

Photocure ASA

Promius Pharmaceuticals

Sanofi

TheraVida

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.14647/fullpdf

Reference19 articles.

1. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice;Pettey;J Am Acad Dermatol,2003

2. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients;Adisen;J Eur Acad Dermatol Venereol,2009

3. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study;Bissonnette;J Eur Acad Dermatol Venereol,2011

4. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis;Au;J Dermatolog Treat,2013

5. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial;Leonardi;Arch Dermatol,2011

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small Molecules in the Management of Psoriasis and Psoriatic Arthritis;Indian Journal of Dermatology;2024-05

2. Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis;American Journal of Clinical Dermatology;2024-03-04

3. Treatment Patterns and Negative Health Outcomes in Palmoplantar Pustulosis Patients in Germany and the US;Dermatology and Therapy;2024-03

4. Phosphodiesterase-4 Inhibition in the Management of Psoriasis;Pharmaceutics;2023-12-22

5. Comparative evaluation of efficacy and tolerability of apremilast and methotrexate in patients of moderate-to-severe palmoplantar psoriasis: A randomized, parallel, open-label clinical trial;Indian Journal of Pharmacology;2023-11